APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application
Open Access
- 3 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 70 (7), 1853-1865
- https://doi.org/10.1007/s00262-020-02814-2
Abstract
Targeting CD40 with agonist antibodies is a promising approach to cancer immunotherapy. CD40 acts as a master regulator of immunity by mobilizing multiple arms of the immune system to initiate highly effective CD8 + T-cell-mediated responses against foreign pathogens and tumors. The clinical development of CD40 agonist antibodies requires careful optimization of the antibody to maximize therapeutic efficacy while minimizing adverse effects. Both epitope specificity and isotype are critical for CD40 agonist antibody mechanism of action and potency. We developed a novel antibody, APX005M, which binds with high affinity to the CD40 ligand-binding site on CD40 and is optimized for selective interaction with Fcγ receptors to enhance agonistic potency while limiting less desirable Fc-effector functions like antibody-dependent cellular cytotoxicity of CD40-expressing immune cells. APX005M is a highly potent inducer of innate and adaptive immune effector responses and represents a promising CD40 agonist antibody for induction of an effective anti-tumor immune response with a favorable safety profile.Keywords
This publication has 41 references indexed in Scilit:
- Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in CancerCancer Research, 2018
- Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder CancerCancer Immunology Research, 2014
- The Use of Agonistic Anti-CD40 Therapy in Treatments for CancerInternational Reviews of Immunology, 2012
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and HumansScience, 2011
- Anti-CD40 agonist antibodies: Preclinical and clinical experienceUpdate on Cancer Therapeutics, 2007
- Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presenting cellsCellular Immunology, 2003
- CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacyNature Medicine, 1999
- Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40Nature Medicine, 1999
- CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell helpNature Medicine, 1999
- CD40 AND CD154 IN CELL-MEDIATED IMMUNITYAnnual Review of Immunology, 1998